SAM
NPCE icon

Silvercrest Asset Management’s Neuropace NPCE Stock Holding History

Silvercrest Asset Management’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.73M Sell
360,065
-36,554
-9% -$548K 0.03% 434
2025
Q4 		$6.12M Buy
396,619
+97,232
+32% +$1.3M 0.04% 407
2025
Q3 		$3.09M Buy
299,387
+641
+0.2% +$6.04K 0.02% 482
2025
Q2 		$3.33M Sell
298,746
-117,791
-28% -$1.47M 0.02% 479
2025
Q1 		$5.12M Buy
+416,537
New +$5.21M 0.04% 406

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Silvercrest Asset Management's NPCE Position: Q1 2026 in Review

Silvercrest Asset Management reduced its Neuropace (NPCE) stake by 9.2% in Q1 2026, selling an estimated $548K and leaving 360,065 shares worth $4.73M. The position accounts for 0.03% of the portfolio, ranked #434.

Silvercrest Asset Management first reported a position in NPCE in Q1 2025 and has held it in 5 quarters since. The position peaked at $6.12M in Q4 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • Silvercrest Asset Management held 360,065 shares of Neuropace worth $4.73M as of Q1 2026.
  • Silvercrest Asset Management sold 36,554 Neuropace shares in Q1 2026, an estimated $548K.
  • Neuropace made up 0.03% of Silvercrest Asset Management's portfolio in Q1 2026, its #434 holding.
  • Silvercrest Asset Management first reported a position in Neuropace in Q1 2025 and has held it in 5 quarters since.
  • Silvercrest Asset Management's Neuropace position peaked at $6.12M in Q4 2025.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Silvercrest Asset Management's 13F filing for Q1 2026, filed 15 May 2026.